The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19 pneumonia
There is no vaccine or antiviral treatment for human coronavirus, so this study aims to evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19 pneumonia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
RECRUITINGShanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
RECRUITINGThe virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7
Time frame: 7 days after randomization
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3
Time frame: 3 days after randomization
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5
Time frame: 5 days after randomization
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: 14 days after randomization
The critical illness rate of subjects at weeks 2
The diagnosis of critical illness case was based on the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4) made by National Health Commission of the People's Republic of China.
Time frame: 14 days after randomization
The mortality rate of subjects at weeks 2
Time frame: 14 days after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.